UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
Unity Biotechnology, Inc. (UBX)
Last unity biotechnology, inc. earnings: 3/11 04:05 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
SAN FRANCISCO, March 07, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the fourth quarter and full year ended December 31, 2024. “We expect to receive 24-week topline data from our Phase 2b ASPIRE study in diabetic macular edema (DME) in this quarter,” said Anirvan Ghosh, Ph.D., chief executive officer of UNITY. “DME remains a significant unmet need, and we believe UBX1325 (foselutoclax) has the potential to provide a differentiated treatment option for patients who continue to experience vision loss despite current standard-of-care therapies. With its novel mechani
Read more
Impact Snapshot
Event Time:
UBX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
UBX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
UBX alerts
High impacting Unity Biotechnology, Inc. news events
Weekly update
A roundup of the hottest topics
UBX
News
- Unity Biotechnology, Inc. (NASDAQ: UBX) had its price target lowered by analysts at Chardan Capital from $6.00 to $4.00. They now have a "buy" rating on the stock.MarketBeat
- Unity Biotechnology, Inc. (NASDAQ: UBX) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $6.00 price target on the stock.MarketBeat
- Unity Biotechnology, Inc. (NASDAQ: UBX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.MarketBeat
- UNITY Biotechnology Appoints Industry Leader and Ophthalmology Expert Yehia Hashad, M.D., to the Board of DirectorsGlobeNewswire
- UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates [Yahoo! Finance]Yahoo! Finance
UBX
Earnings
- 5/14/24 - Beat
UBX
Sec Filings
- 3/31/25 - Form 4
- 3/31/25 - Form 4
- 3/31/25 - Form 4
- UBX's page on the SEC website